La vendita allo scoperto per Emergent BioSolutions dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Emergent BioSolutions. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Emergent BioSolutions (NYSE:EBS) Azioni, Report sulle vendite allo scoperto

Emergent BioSolutions

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Inc

EMPIRE BANCSHARES INC by Empire Bancshares Inc.

Empire Bancshares Inc

Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock is trading higher on Wednesday after the company announced the closing of a $100 million asset-backed<a href="https://www.benzinga.com//node/41138475"> revolving loan facility.</a>
The Details: The new credit facility is aimed at enhancing Emergent&#8217;s liquidity and providing additional financial flexibility to support its operational and strategic initiatives.
At at the end of September, Emergent had a cash balance of about $150 million. Through the new loan facility, Emergent now also has access to up to $100 million in financing.
&#8220;We are pleased to have successfully closed on our new ABL credit facility with favorable terms and an extended maturity, which is further evidence of Emergent&#8217;s strengthened balance sheet and financial position,&#8221; said Joe Papa, president and CEO of Emergent.
How To Buy Emergent BioSolutions Stock
By now you're likely curious about how to participate in the market for Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
See Also: <a href="https://www.benzinga.com/trading-ideas/technicals/24/10/41116889/tesla-stock-speeds-ahead-of-mag7-peers-can-octobers-robotaxi-reveal-keep-the-momentum">Tesla Stock Speeds Ahead Of Mag7 Peers, Can October&#8217;s Robotaxi Reveal Keep The Momentum?</a>
EBS Price Action: At the time of writing, Emergent BioSolutions stock is trading 6.49% higher at $9.02, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: 3196481 from Pixabay.

News

Movers

What's Going On With Emergent BioSolutions Stock Wednesday?

WIIM

Emergent BioSolutions shares are trading higher after the company announced the closing of a $100 million asset-backed loan facility.

Emergent Biosolutions Announced The Closing Of Credit Agreement Worth $100M Entered On September 30, 2024 Providing For An Asset-based Revolving Loan Facility

Emergent BioSolutions shares are trading higher after CA Gov. Gavin Newsom signed a bill pushing for Narcan in workplace first aid kits.

<a href="https://www.latimes.com/california/story/2024-09-28/california-naloxone-first-aid-kits">https://www.latimes.com/california/story/2024-09-28/california-naloxone-first-aid-kits</a>
Workplaces in California could eventually be required to stock their first aid kits with naloxone or another medication that can stop an opioid overdose under <a href="https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202320240AB1976">a bill</a> signed this week by Gov. Gavin Newsom.
Naloxone, commonly sold under the brand name Narcan, can prevent someone from dying of an opioid overdose if administered promptly by a bystander. The medicine binds to the same receptors in the brain as opioids such as fentanyl, which allows the medicine to displace the opioids and reverse their effects.
Assembly Bill 1976 requires California regulators to craft rules requiring first aid kits in workplaces to contain naloxone or any similar medication approved by the Food &amp; Drug Administration. Such a proposal would have to go before a state board for possible adoption by Dec. 1, 2028.
The bill was <a href="https://www.latimes.com/california/story/2024-01-31/to-prevent-opioid-overdoses-california-bill-would-require-naloxone-in-workplace-first-aid-kits">proposed by Assemblymember Matt Haney</a> (D-San Francisco) and supported by the California Emergency Nurses Assn. and a long list of law enforcement groups. Haney argued that it would dramatically increase the accessibility of naloxone, enabling more lives to be saved.
"If fentanyl continues to be more accessible than naloxone, we're going to keep seeing an increase in overdose deaths in our communities," he said in a statement.
Earlier this summer, AB 1976 was opposed by the National Electrical Contractors Assn. and other groups tied to the construction industry. The groups argued that the decision should be left to the Occupational Safety and Health Standards Board, which could decide whether a mandate made sense for all employers. For instance, they raised concerns about storing Narcan safely at construction sites that are not temperature controlled.
In recent months, however, the bill was amended to only require the Occupational Safety and Health Board to consider such a proposal — not to mandate that such rules be adopted. After that and other changes, NECA and other industry groups dropped their opposition, according to a lobbyist for its California chapter.
The state board focused on occupational safety has already been weighing the idea: Earlier this year, it reviewed a petition from the National Safety Council, a group that aims to eliminate leading causes of preventable deaths, to require employers to provide naloxone at all work sites.
Cal/OSHA concluded that doing so would lead to a "significant reduction in opioid-related deaths in California," with deadly injuries resulting from overdoses at work having risen between 2018 and 2022 from 23 to 117, according to a <a href="https://www.dir.ca.gov/oshsb/documents/petition-602-adopteddecision.pdf">state report</a>. But staff of the Occupational Safety and Health Board cautioned that mandating naloxone in workplace first aid kits could be "unnecessarily burdensome" for some employers.
The state board <a href="https://www.dir.ca.gov/oshsb/documents/petition-602-adopteddecision.pdf">decided</a> that exceptions could be made for employers who face practical barriers to storing or administering the medication. In June, it asked Cal/OSHA to convene an advisory committee to consider changing the state rules in order to require "ready access by employees to opioid antagonists."
AB 1976 will push that process along, advocates said, by setting a deadline for the board to consider such changes.

Biotech

Politics

General

'Newsom Signs Bill Pushing For Narcan In Workplace First Aid Kits' - LA Times

<a href="https://www.wsj.com/business/amazon-to-stock-opioid-overdose-reversal-drug-narcan-at-its-warehouses-2ea8d831" title="https://www.wsj.com/business/amazon-to-stock-opioid-overdose-reversal-drug-narcan-at-its-warehouses-2ea8d831">https://www.wsj.com/business/amazon-to-stock-opioid-overdose-reversal-drug-narcan-at-its-warehouses-2ea8d831</a>

AMZN

'Amazon to Stock Opioid Overdose Reversal Drug Narcan at Its Warehouses' -Wall Street Journal Report

<h3>Gainers</h3>
<ul>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock moved upwards by 66.4% to $6.4 during Thursday's regular session. The market value of their outstanding shares is at $6.6 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares increased by 49.13% to $3.46. The market value of their outstanding shares is at $6.1 million. </li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares rose 28.62% to $5.14. The company's market cap stands at $758.7 million. </li>
<li>Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) stock increased by 25.64% to $4.36. The company's market cap stands at $272.0 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock increased by 20.3% to $1.25. The market value of their outstanding shares is at $6.7 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock rose 18.51% to $7.04. The market value of their outstanding shares is at $368.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) stock decreased by 19.4% to $1.75 during Thursday's regular session. The market value of their outstanding shares is at $91.3 million. As per the news, the H1 earnings report came out yesterday. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares declined by 18.99% to $1.92. The company's market cap stands at $2.5 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares decreased by 14.47% to $5.64. The market value of their outstanding shares is at $8.2 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares declined by 13.31% to $8.34. The company's market cap stands at $13.0 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares fell 11.02% to $0.6. The company's market cap stands at $4.5 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock decreased by 10.17% to $1.67. The market value of their outstanding shares is at $21.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADPT

ERNA

FBRX

FULC

KAPA

KTTA

LUCY

TBIO

TOVX

12 Health Care Stocks Moving In Thursday's Intraday Session

Emergent BioSolution shares are trading higher after the company announced that two contract options have been secured to procure additional treatment courses of TEMBEXA to sustain the U.S. government's national preparedness posture against human smallpox.

Emergent BioSolutions Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) ("Emergent") today announced that two contract options have been secured to procure additional treatment courses of TEMBEXA&#xAE; (brincidofovir) to sustain the U.S. government's national preparedness posture against human smallpox. TEMBEXA&#xAE; is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The order is valued at $67.4 million and executes procurement options CLIN0004A and CLIN0005A under Emergent's existing <a href="https://www.globenewswire.com/Tracker?data=djyD7sABmBk1yf6GemRN-78PCdLUCUEILbW0T7FICIzw8ndOPvJSbqfFwkDZDrI_i4RfOeZpKX6kNcnggSlrYRtSPeFBZ9ukphhl3d-Yt1HxunOO_y0TbVCeKnD0LGRMafk1io2mxDTF9mMtUHtJC9Rm4DmfR-ByGrsuZ4G-Igt9x3GkusFXw8RKmrIdzCLrLvRB_mcW_1epmeIUWdtK-coN01OSB2IVx2QIjcCR_wFvA800MvXraKpUNWJaKnN3">10-year contract</a>.

Contracts

Emergent BioSolutions Announces The Execution Of Contract Options Valued At $67.4M To Procure Additional TEMBEXA To Support National Preparedness Efforts

On Wednesday, Emergent BioSolutions Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) said it secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox, and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41021297/emergent-biosolutions-confirms-approximately-400-million-in-orders-in-2024-2025-to-support-smallpo" rel="noreferrer noopener">mpox product portfolio</a>.
What Happened: The order includes the previously disclosed&nbsp;U.S. government contract modification&nbsp;to procure ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live), as well as CNJ-016&nbsp;[Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) contract options exercised <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39602092/why-is-vaccine-maker-emergent-biosolutions-stock-trading-higher-on-tuesday" rel="noreferrer noopener">in&nbsp;2023&nbsp;and&nbsp;2024</a>.
To date, in 2024, nearly $210 million in customer orders have been delivered for ACAM2000&nbsp;and VIGIV.
For the remainder of 2024 and into 2025, Emergent is confirmed to deliver more than $185 million in ACAM2000 and VIGIV orders.
&#8220;Emergent co1ntinues to be a trusted partner to supply medical countermeasures for biodefense and global health preparedness, and these incremental orders demonstrate our ongoing leadership to help address serious viral threats like smallpox and mpox,&#8221; said Joe Papa, president and CEO of Emergent.
Why It Matters: In August, the FDA approved Emergent BioSolutions&#8217; supplemental Biologics License Application (sBLA)&nbsp;to expand the indication for ACAM2000 to include preventing mpox disease in individuals at high&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40649541/mpox-vaccine-emergent-biosolutions-smallpox-vaccine-gets-fda-nod-for-expanded-use-for-individuals" rel="noreferrer noopener">risk for mpox infection</a>.
Shortly after, Emergent&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=EzQNYDD8pjtoG0gZzPCrG3pNpuayyfCXiLNpEwRuNQeXZCSjZPieHKbrFjIlQ6LthEsBPtCl2YoAr32DdkOrKgYmRck1tI9jw9Csclvb-DBrRN4ZcsnFimIlLvkIVTA7OMfhLX9Rz8PWUS6XTJRHZuvZv7FyFwtw1_p3I81lKppGQdmnoDbE1M1s2YOZlkfiobjdbi5T98mDUJI7CFCLnS-nY2jaaMEOuKWt-LKaI1g_E83TYZBq7F4mtGkYFfb026H5va42kZ2TP7mEmKP1aKHST2zxTD8uCiP51PpIG-38SyuoKHWlnseAJyL1HaG2poVAmXYZE9hDFMC9HVwRyLAsSMnZy3Mvv9v1Y5mCnq-ToHmuQfXCWDrekdJu5ywMj7CrT5OghPd5H2abWQMrZN0Jz5oizAyZlsfW8jrDxXY=" rel="noreferrer noopener">announced</a> that it submitted an Expression of Interest for the ACAM2000 vaccine to be assessed for Emergency Use Listing (EUL) with the&nbsp;World Health Organization&nbsp;(WHO).
In furtherance of its commitment to support mpox response efforts,&nbsp;Emergent has donated 50,000 doses of ACAM2000 for potential deployment across impacted countries across the African continent.
Last month, Emergent BioSolutions reported second-quarter 2024 sales of $254.7 million, down 25% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40226161/vaccine-maker-emergent-biosolutions-expects-deeper-losses-in-2024-stock-sinks" rel="noreferrer noopener">consensus of $190 million</a>.
The company reported an adjusted EPS loss of $(2.32), more than double the $(1.05) reported a year ago,&nbsp;missing the consensus of $(0.94).
Emergent BioSolutions updated its 2024 Revenue guidance from $1 billion—$1.1 billion to $1.05 billion—$1.125 billion, versus the consensus of $1.03 billion.
Price Action: EBS stock is down 3.7% at $5.88 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41024832/eli-lilly-touts-results-of-eu-approved-dermatitis-treatment-shows-sustained-disease-control-for-u" target="_blank" rel="noreferrer noopener">Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years</a>.</li>
</ul>
Photo: Unsplash

Government

Health Care

Trading Ideas

Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines

Emergent BioSolutions shares are trading higher after the company announced  it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio.

Emergent BioSolutions Announced It Has Secured Approximately $400M In Orders In 2024 And 2025 Associated With Its Vaccinia, Smallpox And Mpox Product Portfolio

<a href="https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.">https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.</a>
&nbsp;
Los Angeles County health officials are reporting a significant uptick in mpox cases, prompting renewed calls for vaccination among&nbsp;high-risk&nbsp;groups.
The County's Department of Public Health announced that 52 mpox cases were reported in the past four weeks, compared to 24 in the previous&nbsp;four-week&nbsp;period.&nbsp;
About 70% of new cases in the last six months occurred in&nbsp;unvaccinated&nbsp;individuals.
Health officials strongly recommend vaccination for several high-risk groups, including men and transgender people who have sex with men or transgender persons, persons of any gender or sexual orientation who have sex or intimate physical contact with others in association with large public events or engage in commercial and/or transactional sex, and those living&nbsp;with&nbsp;HIV.
"Vaccination is an important tool in preventing the spread of mpox," the County health department said in a statement. The two-dose JYNNEOS vaccine is available at pharmacies for insured residents and at Los Angeles County Department of Public Health Clinics for free&nbsp;without&nbsp;appointments.
Officials advise residents to practice safe sex, limit sexual partners, and avoid intimate contact with anyone showing mpox symptoms, which include rash, fever, and swollen lymph nodes. Additional prevention measures include asking partners about symptoms, reducing the number of partners, and proper use of condoms&nbsp;and&nbsp;gloves.
The County emphasizes the importance of testing for those who develop symptoms consistent with mpox. The Department of Public Health is collaborating with healthcare providers and community organizations to intensify surveillance, contact tracing, and outbreak investigations to&nbsp;curb&nbsp;transmission.
Mpox, previously referred to as Monkeypox, is mainly spread through close physical contact. Residents seeking more information can visit<a href="http://ph.lacounty.gov/mpox"> ph.lacounty.gov/mpox</a> or call the Department of Public Health Call Center&nbsp;at&nbsp;1-833-540-0473.

Macro Economic Events

Economics

AEMD

APDN

CMRX

GOVX

MRNA

TNXP

VRAX

'Mpox Cases Double In Los Angeles County, Health Officials Urge Vaccination; Los Angeles County Public Health Officials Report Increase, Recommend Prevention Measures' - Pasadena Now

<a href="https://www.youtube.com/watch?v=ZFW3ONApp4w" title="https://www.youtube.com/watch?v=ZFW3ONApp4w">https://www.youtube.com/watch?v=ZFW3ONApp4w</a>

Macro Notification

Biden On Sudan Says End This War Now; Let's Move Quickly To Face Mpox Outbreak In Africa

-Reuters Citing Senior Administration Official

President Biden Will Announce Donation Of 1M MPox Vaccine Doses, At Least $500M To African Countries To Support Their Response To Outbreak

CDC Says No Cases Of Clade IA Mpox Have Been Reported Outside Central African Countries Where Clade IA MPVX Is Endemic

US To Stay Committed In Bringing Mpox Outbreak Under Control

Rodman &amp; Renshaw analyst Brandon Folkes reiterates Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) with a Buy and maintains $16 price target.

Price Target

Reiteration

Analyst Ratings

Rodman & Renshaw Reiterates Buy on Emergent BioSolutions, Maintains $16 Price Target

Legal

Emergent Biosolutions Has Entered Into An Agreement To Resolve The Previously Disclosed Securities Class Action Litigation, Emergent Will Pay $40M To Settle Claims

Morocco Records First Case Of Mpox

Morocco reports first mpox case amid ongoing global outbreak

Emergent Bio to pay $40M to settle class action lawsuit

The 1-Minute Market Report September 22, 2024

U.S. to donate 1M mpox shots to address outbreak in Africa: report

Emergent Bio gains after confirming $400M orders for 2024/25

Emergent Bio gains after U.S. govt. order for smallpox therapy

Amazon to provide opioid overdose drug in workplace

Emergent Biosolutions ( ($EBS) ) has provided an announcement. Emergent BioSolutions Inc. secured a new $100 million asset-backed revolving loan fa...

Emergent Biosolutions Secures Loan, Bolsters Growth Strategy

Emergent Biosolutions ( ($EBS) ) has provided an update. Emergent BioSolutions Inc. has decided to reward Richard S. Lindahl, the company's Executi...

Emergent BioSolutions Grants CFO Stock for Contributions

Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario

ACTV

AFMC

AFSM

ARKK

AVUV

BAPR

BITO

BIZD

BVNKF

BVNRY

CHRS

CODX

COPX

CRMT

CRNC

DCOM

ICLN

ITOS

IVOO

IVOV

KCCA

KRBN

LSCC

MAGS

MLKN

MODV

MSOS

PALL

PAVE

PGNY

POWL

RHHBF

RHHBY

SIGA

SLVM

SPLV

SPMD

SPMO

SPMV

SPSM

SPUS

SPUU

SPVM

SPVU

SPWRQ

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SSLY

SSPY

SVAL

SYLD

TEVA

TMDV

TPHD

TPLC

TPSC

UAUG

UFPT

UJAN

UMAR

UMAY

UOCT

UPRO

URNM

USMC

USMF

USVM

UTWO

Screenshot 2024-09-18 at 12.30.33 AM

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Press Releases

Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness

Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile

Management

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Financing

OHA is Administrative Agent and Sole Lender for Emergent BioSolutions Debt Refinancing

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

Comments

Emergent BioSolutions

Vendite allo scoperto

Emergent BioSolutions (NYSE:EBS) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO